UWA-101 hydrochloride
UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC50 values of 3.6 µM and 2.3 µM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease.
For research use only. We do not sell to patients.
- CAS No.: 1431520-52-3
- Formula: C13H18ClNO2
- Molecular Weight:255.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (250-300 g; Parkinson's disease model)[1].
-
Dosage:3 mg/kg
-
Administration:Intraperitoneal injection
-
Result:Reduced L-DOPA-induced vertical activity by 60%.
Chemical Information
-
CAS No. 1431520-52-3
-
Molecular Weight 255.74
-
Formula C13H18ClNO2
-
SMILES
CNC(C1CC1)CC2=CC=C3OCOC3=C2.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Johnston TH, et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. FASEB J. 2012 May;26(5):2154-63. [Content Brief]
[2]. Huot P, et al. Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis. 2015;2015:609428. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)